Ryan S. Huss

Internal Medicine

300 Pasteur Dr
Stanford, CA 94305

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Journal: Nature medicine

Published: June 18, 2025

Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.

Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.

Journal: Journal of lipid research

Published: July 02, 2022

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.

Journal: Gut

Published: May 03, 2022

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.

Journal: Journal of lipid research

Published: April 20, 2022

Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH.

Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH.

Journal: Cell reports. Medicine

Published: April 14, 2022

IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.

IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.

Journal: Hepatology (Baltimore, Md.)

Published: February 17, 2022

Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance.

Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance.

Journal: AJR. American journal of roentgenology

Published: February 02, 2022

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.

Journal: Hepatology (Baltimore, Md.)

Published: December 03, 2021

Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.

Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: November 05, 2021

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.

Journal: Journal of hepatology

Published: September 28, 2021

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

Journal: Journal of hepatology

Published: July 07, 2021

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.

Journal: Hepatology (Baltimore, Md.)

Published: March 30, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026